Acquired Company
Jazz acquired Chimerix on 4/21/2025 for $8.55 per share in cash, representing a total transaction value of approximately $935 million.
Chimerix, Inc., a developing-stage biopharmaceutical company, focuses on accelerating the advancement of various drugs that impact the lives of patients living with cancer and other serious diseases. The company is headquartered in Durham, North Carolina. Show more
2505 MERIDIAN PARKWAY, DURHAM, NC, UNITED STATES, 27713, Durham, NC, 27713, USA
Market Cap
801.1M
52 Wk Range
$0.00 - $0.00
Previous Close
$8.54
Open
$8.54
Volume
N/A
Day Range
$8.54 - $8.54
Enterprise Value
0.00
Cash
31.05M
Avg Qtr Burn
-19.27M
Insider Ownership
1.73%
Institutional Own.
56.44%
Qtr Updated
03/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TEMBEXA (brincidofovir) Details Smallpox | Approved Quarterly sales | |
ONC206 Details Brain tumor, Solid tumor/s, Glioblastoma | Phase 1 Data readout | |
Dociparstat sodium (DSTAT) Details Infectious disease, COVID-19 | Failed Discontinued | |
Dociparstat sodium (DSTAT) Details Cancer, Acute myeloid leukemia | Failed Discontinued |
